Clinical Trial Update: Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the pharmacokinetics and pharmacodynamics of a single subcutaneous dose of ZP4207 in hypoglycemic Type 1 diabetes patients, using m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoglycemia
• Type 1 Diabetes Mellitus

Drugs mentioned

• GLUCAGON (GLUCAGON)
• ZP4207

Snippet

Sponsor: Zealand Pharma | Conditions: Hypoglycemia | Phase 2 | Status: COMPLETED